What Experts Really Think About Diet Soda
Growing up, Olivia Dreizen Howell, 39, “lived on” diet soda. So did her family. At a family reunion in 1996, everyone sported T-shirts with their shared surname in Diet Coke-can font. “We drank Diet Coke, Diet ginger ale, and Diet Sprite like water—there was no difference in our household,” she says.
Like many, Howell believed that sugar-free soda was a benign choice. But the latest research casts doubt on that assumption, linking diet drinks to mood disorders, fatty liver development, autoimmune diseases, and cancer, to name a few.
[time-brightcove not-tgx=”true”]
Bef...
Source: TIME: Health - April 9, 2024 Category: Consumer Health News Authors: Perri Ormont Blumberg Tags: Uncategorized Evergreen freelance healthscienceclimate Source Type: news
Scientists Find New Genetic Variants for Obesity
Researchers believe they have discovered a new biological mechanism for obesity, pointing to rare variants on two genes that dramatically increase the risk of carrying excess weight.
Research published in the journal Nature Genetics on Thursday points to variants that raise the chance of being obese by as much as six times. Unlike other known variants that affect weight gain in children, these only appear to play a role in adults.
[time-brightcove not-tgx=”true”]
Unraveling obesity’s mechanisms could help scientists develop new drugs, or tailor existing ones, for a condition that now affects ...
Source: TIME: Health - April 4, 2024 Category: Consumer Health News Authors: Ashleigh Furlong/Bloomberg Tags: Uncategorized healthscienceclimate wire Source Type: news
Scientists find new 'fat genes' that make you six times more likely to be obese - and up to 10,000 Brits carry them
Researchers at the University of Cambridge also found the genetic quirk was linked with an increased risk of non-alcoholic fatty liver disease and of type 2 diabetes. (Source: the Mail online | Health)
Source: the Mail online | Health - April 4, 2024 Category: Consumer Health News Source Type: news
Monthly News Roundup - March 2024
Rezdiffra Approved as First Drug for Nonalcoholic Fatty Liver Disease (NASH)
In March, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra (resmetirom) for adults with noncirrhotic nonalcoholic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2024 Category: Pharmaceuticals Source Type: news
Aspirin for Fatty Liver; Meds for Self-Managed Abortion
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 30, 2024 Category: Cardiology Source Type: news
FDA approves first drug for NASH — a severe form of fatty liver disease
A Yale Medicine expert discusses Rezdiffra, a new treatment for a serious subtype of fatty liver disease that is not caused by heavy alcohol use. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 25, 2024 Category: Universities & Medical Training Source Type: news
Ultrasound model predicts liver disease progress
A predictive model combining multiple ultrasonic parameters could discriminate between different liver diseases in a study published March 19 in Radiology.
A team of researchers led by Fangyi Liu, MD, from the Chinese PLA General Hospital in Beijing, found that their multiparametric ultrasound model can predict metabolic dysfunction-associated steatohepatitis (MASH) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD), regardless of hepatitis B virus infection status.
“These findings are important for noninvasive assessment of the MAFLD disease process,” the Liu team wrote.
Previous studies ...
Source: AuntMinnie.com Headlines - March 20, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Clinical News Ultrasound Genitourinary Radiology Source Type: news
US FDA approves first drug for fatty liver disease NASH
(Source: Reuters: Health)
Source: Reuters: Health - March 15, 2024 Category: Consumer Health News Source Type: news
FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
The FDA approved the first medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 14, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Ionis Pharma's Fatty Liver Disease Drug Succeeds in Mid-stage Trial Ionis Pharma's Fatty Liver Disease Drug Succeeds in Mid-stage Trial
Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the critical organ in a...Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 13, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Ozempic Eases Fatty Liver Disease in People Living With HIV
THURSDAY, March 7, 2024 -- There ' s more good news around the diabetes and weight-loss drug Ozempic: It might help ease fatty liver disease in people living with HIV, new research shows.Six months of weekly injections of Ozempic (semaglutide)... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 7, 2024 Category: General Medicine Source Type: news
2 Bay Area biotechs look to raise collective $550 million following deal, trial news
Akero disclosed midstage trial data Monday for its treatment for the fatty liver disease MASH, while BridgeBio announced a deal Sunday to license its heart failure drug to Bayer in Europe. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 4, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Akero's Fatty Liver Disease Drug Lessens Scarring in Mid-stage Trial Akero's Fatty Liver Disease Drug Lessens Scarring in Mid-stage Trial
Akero Therapeutics ' experimental drug for a type of fatty liver disease significantly reduced scarring after nearly two years in a mid-stage study, it said on Monday, as the...Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 4, 2024 Category: Pathology Tags: Gastroenterology Source Type: news
Symptoms of fatty liver disease to spot as condition linked to higher dementia risk
Around one in three adults in the UK is thought to be living with the early stages of fatty liver disease. (Source: Daily Express - Health)
Source: Daily Express - Health - March 3, 2024 Category: Consumer Health News Source Type: news
Zydus aims to launch first new drug in US by early 2026
Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition of CymaBay for $4.3 billion earlier in February. Saroglitazar, currently in a mid-to-late-stage trial for PBC, is also being tested for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2024 Category: Pharmaceuticals Source Type: news
